Coagulo’s testing platform is transforming diagnosis and treatment for the most vulnerable patient populations.

Coagulation testing in pediatrics, especially neonates and infants, often requires phlebotomy (blood draw) and large volumes of blood. Diagnosis of patients with coagulopathies, such as hemophilia, or monitoring patients on anticoagulants, such as those on Extra Corporeal Life Support (ECLS), can lead to iatrogenic anemia due to the large amount of blood required for diagnosis and treatment monitoring. Phlebotomies are currently one of the primary causes of neonatal anemia, requiring blood transfusions.

Coagulo is the first testing solution to identify factor-specific abnormalities and quantify coagulation status using merely drops of blood, allowing for a less invasive, more rapid diagnostic tool that does not result in additional harm to such vulnerable patients. Recent research studies have also demonstrated rapid detection of anticoagulation resistance, particularly in patients who developed blood clots.